<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748278</url>
  </required_header>
  <id_info>
    <org_study_id>UW 15-547</org_study_id>
    <nct_id>NCT02748278</nct_id>
  </id_info>
  <brief_title>Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment</brief_title>
  <official_title>Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women Undergoing in Vitro Fertilization Treatment With a Standard Ovarian Stimulation Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IVF is a well-established method to treat various causes of infertility. Some studies have
      suggested that ethnicity affects the success of IVF. This is a prospective study involving
      two tertiary IVF units in Hong Kong and Australia. The IVF outcome between Chinese and
      Caucasians will be compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study conducted in two tertiary IVF units in Hong Kong and Australia.

      The target population for the trial will be women undergoing IVF or intracytoplasmic sperm
      injection (ICSI) treatment in two IVF Units.

      Intervention:

      Patients recruited in this study will undergo IVF+/-ICSI treatment. They will undergo an
      ultrasound scan on the second or third day (day 2 or 3) of a period to exclude the presence
      of ovarian cyst and have the antral follicle count determined, which includes all follicles
      of 2-10 mm measured with a 5.5-7.5mHz transvaginal ultrasound probe. Blood will be checked
      for anti-mullerian hormone (AMH) measured by Beckman-Coulter Diagnostics.

      Ovarian stimulation will be started if there are no ovarian cysts on ultrasound scan. They
      will receive one long acting gonadotrophin injection Elonva 150 microgram subcutaneously
      followed by daily gonadotrophin injections (Puregon) 200 IU in an antagonist protocol.
      Antagonist (orgalutran 0.25 mg) will be started on day 5 of ovarian stimulation. Transvaginal
      ultrasound will be performed for follicular tracking 7 days after the Elonva injection and
      every 1-3 days thereafter. No adjustment in FSH dose is allowed. Cycles will be cancelled if
      there are less than 3 follicles larger than 18mm after one week of 200 IU Puregon or there no
      developing follicle (i.e. larger than 11mm) after one week of 200 IU Puregon.

      Recombinant hCG (Ovidrel, Serono, Bari, Italy) 0.25mg will be given if there are 2 follicles
      &gt;18 mm in diameter. Gonadotrophin injection will not be given on the day of hCG. Agonist
      trigger will be used if oestradiol concentration on the day of trigger is greater than 15,000
      pmol/L or there are more than 15 follicles &gt;16mm on transvaginal scanning. All embryos or
      blastocysts will be frozen for transfer later following agonist trigger or when the number of
      oocytes aspirated is 20 or more. Serum FSH, oestradiol, LH and progesterone concentrations
      are taken 7 days after the Elonva injection and hCG trigger day. Transvaginal
      ultrasound-guided oocyte retrieval (TUGOR) will be scheduled on Mondays, Wednesdays and
      Fridays, 34-36 hours after the hCG injection. Flushing of follicles will not be performed.
      Follicular fluid not contaminated with blood will be collected from the first and largest
      follicle on each side for estradiol and progesterone level.

      The retrieved oocyte will be inseminated conventionally or by ICSI, depending on the semen
      parameters. ICSI is advised if the total motile sperm number after sperm preparation &lt; 0.2
      million, sperm morphology by strict criteria &lt; 3% or fertilization rate &lt; 30% in previous IVF
      cycles with conventional insemination. One to two embryos will be replaced on day 2-5 after
      oocyte retrieval. Luteal phase support will be started according to the standard protocol of
      the centre. Patients will be followed up for urinary pregnancy test 16 days after embryo
      transfer. Patients with a positive pregnancy test will have transvaginal ultrasound scan
      performed 10-14 days later and are referred for antenatal care at 8-10 weeks gestation. The
      remaining embryos will be frozen. Pregnancy outcome will be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes obtained</measure>
    <time_frame>17 days</time_frame>
    <description>Number of oocytes obtained</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of follicles smaller than 14, 16mm and larger than 18mm in diameter on day 8 and day of hCG</measure>
    <time_frame>8 and day of hCG</time_frame>
    <description>Number of follicles smaller than 14, 16mm and larger than 18mm in diameter on day 8 and day of hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of recombinant FSH</measure>
    <time_frame>15 days</time_frame>
    <description>Duration of recombinant FSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of recombinant FSH</measure>
    <time_frame>15 days</time_frame>
    <description>Dosage of recombinant FSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum estradiol levels on day 9 and day of hCG</measure>
    <time_frame>9 and day of hCG</time_frame>
    <description>Serum estradiol levels on day 9 and day of hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum FSH levels on day 9 and day of hCG</measure>
    <time_frame>9 and day of hCG</time_frame>
    <description>Serum FSH levels on day 9 and day of hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LH levels on day 9 and day of hCG</measure>
    <time_frame>9 and day of hCG</time_frame>
    <description>Serum LH levels on day 9 and day of hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum progesterone levels on day 9 and day of hCG</measure>
    <time_frame>9 and day of hCG</time_frame>
    <description>Serum progesterone levels on day 9 and day of hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Miscarriage rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical pregnancy rate: presence of intrauterine gestational sac at 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Ongoing pregnancy rate: presence of fetal heart pulsation on transvaginal scan at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>44 weeks</time_frame>
    <description>Live birth rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian hyperstimulation rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Ovarian hyperstimulation rate (according to RCOG guideline)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Subfertility</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transvaginal ultrasound-guided oocyte retrieval</intervention_name>
    <description>Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embryo transfer</intervention_name>
    <description>One or two embryos will be replaced on day 2-5 after oocyte retrieval.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be saved for genetic study if there is significant difference in the number of
      oocytes obtained between Chinese and Caucasian women.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women undergoing IVF or intracytoplasmic sperm injection (ICSI) treatment in the two study
        sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women age 18-36 years old

          -  Body weight &gt;60Kg

          -  Total antral follicle count &gt;=7 and â‰¤ 20 i.e. not poor ovarian reserve based on
             Bologna criteria

          -  Chinese women in the HK centre and Caucasian women (defined as originating from the
             United Kingdom, Europe or United States of America, excluding the Middle East) in the
             Australian centre

          -  Written informed consent

        Exclusion Criteria:

          -  Mixed race/ ethnicity

          -  History of ovarian surgery

          -  Body mass index &gt;35 kg/m2

          -  &gt;2 previous stimulated IVF cycles

          -  History of ovarian hyperstimulation syndrome in previous stimulated IVF cycles

          -  Polycystic ovary syndrome or total antral follicle count &gt;20
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest HY Ng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynaecology, 6/F, Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ernest HY Ng</last_name>
    <phone>852-22553400</phone>
    <email>nghye@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynaecology</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest HY NG, MD</last_name>
      <phone>852-22553400</phone>
      <email>nghye@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Ernest HY NG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>subfertility</keyword>
  <keyword>In-vitro fertilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

